Drug intelligence / Profile preview

GEN1057

Development stage: Discontinued
Lead developer: Genmab
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GEN1057 is an investigational bispecific antibody developed using Genmab's DuoBody technology. It is designed for the treatment of advanced or metastatic malignant solid tumors. The drug is currently being evaluated in a first-in-human, open-label, phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity as monotherapy in patients with advanced solid tumors who have not responded to standard therapies. The antibody targets two distinct antigens—fibroblast activation protein alpha (FAPα) and death receptor 4 (DR4)—to potentially enhance anti-tumor immune responses and induce tumor cell apoptosis[1][2][4][5][7].

Other names: DuoBody-FAPαxDR4

Targets

TNFRSF10A (Death receptor 4)FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on GEN1057.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN1057.

Explore the full profile